Ikena Oncology, Inc. (IKNA)
Ikena Oncology, Inc. is a clinical stage biotechnology company, which engages in the development of patient directed and biomarker driven therapies for cancer patients. Its product pipeline includes IK-930, RAS Signaling, IK-175, IK-412, and IK-007. The company was founded by Mark Manfredi and George Georgiou in February 2016 and is headquartered in Boston, MA.
Address
50 NORTHERN AVE.
BOSTON, MA 02210
Founded
2016
Number of Employees
43
Website
http://www.ikenaoncology.com
Buyback
| Buyback Data | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | Average |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $ Amount Purchased ($ in 000s) |
- | - | - | - | - | - | - | - | - | $663 | - | $663 |
| Average Price | - | - | - | - | - | - | - | - | - | $6.80 | - | $6.80 |
| # Shares Purchased | - | - | - | - | - | - | - | - | - | 97,500 | - | 97,500 |
| Buyback Performance | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | Average |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Return to Date | - | - | - | - | - | - | - | - | - | -85.3% | - | -85.3% |
| S&P 500 Return to Date | - | - | - | - | - | - | - | - | - | 31.3% | - | 31.3% |
| Excess Total Return | - | - | - | - | - | - | - | - | - | -116.6% | - | -116.6% |
| Quartile Rank |
|
|
|
|
|
|
|
|
|
|
|
|
| Percentile Rank | - | - | - | - | - | - | - | - | - | 1% | - | 3% |
Buyback returns calculated using weighted average buyback price over the last 10 years and comparing to current day stock price value. S&P 500 used as benchmark for excess return.
Insider Transactions
Filters
Keyboard Shortcuts: Show (a) | Close (Esc)
Never miss an email alert when insiders at IKNA make a trade.
Creating a free account takes less than one minute